Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014

Shots:

• UBE to receive up front, development & commercial milestones and royalties on sales. Novo Nordisk to get exclusive WW license to UBE’s preclinical asset UD-014 and will be responsible for development, manufacturing and commercialization of UD-014
• The collaboration will widen Novo Nordisk’s presence and investment in NASH and will provide more treatment options to the patients living with NASH
• UBE’s UD-014 is a selective semi carbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor, demonstrating efficacy in preclinical studies for its anti-inflammatory MOA and antioxidative effect on endothelial cells, potentially used for NASH

Click here to­ read full press release/ article | Ref: UBE | Image: The Local Denmark